SUMMARY
Previous research has indicated that circulating microRNAs are linked to the onset and progression of type 1 diabetes mellitus (T1DM), making them potential biomarkers for the disease. In this study, we employed a multiplatform sequencing approach to analyze circulating microRNAs in an extended cohort of individuals recently diagnosed with T1DM from the European INNODIA consortium. Our findings revealed that a specific set of microRNAs located within the T1DM susceptibility chromosomal locus 14q32 distinguishes two distinct subgroups of T1DM individuals. To validate our results, we conducted additional analyses on a second cohort of T1DM individuals, independently confirming the identification of these two subgroups, which we have named Cluster A and Cluster B. Remarkably, Cluster B T1DM individuals, who exhibited increased expression of 14q32 miRNAs, displayed a different peripheral blood immunomics profile, possessed a lower T1DM risk HLA genotype, and showed better glycaemic control during follow-up visits compared to Cluster A individuals. Taken together, our findings suggest that this specific set of circulating microRNAs located in the 14q32 locus can effectively identify T1DM subgroups with distinct characteristics and different clinical outcomes during follow-up.
HIGHLIGHTS
Circulating miRNA profiles in individuals with newly diagnosed Type 1 Diabetes Mellitus (T1DM) can distinguish two subgroups: Cluster A and Cluster B.
miR-409-3p, miR-127-3p, and miR-382-5p are increased in the plasma of individuals in Cluster B.
Individuals in Cluster B showed lower IAA titers, a reduced prevalence of HLA risk genotype, and an improved glycaemic profile during the follow-up period.
Immunomic profiling revealed a reduced frequency of pro-inflammatory immune cells and a higher frequency of exhausted T lymphocytes among individuals in Cluster B.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work is supported by the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement No.115797-INNODIA and No.945268 INNODIA HARVEST. This joint undertaking receives support from the EU Horizon 2020 research and innovation programme and EFPIA, JDRF and The Leona M. and Harry B. Helmsley Charitable Trust. GS is supported by University of Siena within F-CUR funding program Grant No. 2268-2022-SG-PSR2021-FCUR_001. FD was supported by the Italian Ministry of University and Research (2017KAM2R5_003). This work is also supported by EU within Italian Ministry of University and Research (MUR) PNRR National Center for Gene Therapy and Drugs based on RNA Technology (Project No. CN00000041 CN3 Spoke 5 Inflammatory and Infectious Diseases. This work is also supported by JDRF and The Leona M. and Harry B. Helmsley Charitable Trust for the project: Collaborative Effort to Identify and Validate miRNA as Biomarkers of T1D.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study followed the guidelines of the Declaration of Helsinki for research on human individuals, and the study was approved by the local ethical committees of the participating clinical sites: CHL - Centre Hospitalier de Luxembourg, Luxembourg HH-RH - Herlev University Hospital, Copenhagen-Denmark HKA - Hannoversche Kinderheilanstalt, Hannover-Germany IT- Ospedale Pediatrico Bambino Gesu, Roma- Italy KU Leuven, Leuven- Belgium MUG - Medical University of Graz, Graz- Austria SUM - Slaski Uniwersytet Medyczny w Katowicach, Katovice, Poland UCAM - University of Cambridge, Cambridge- UK UH - University of Helsinki, Helsinki- Finland UK- Barts Health NHS Trust, London- UK UK - Leicester Royal Infirmary, Leicester- UK ULB - Universite Libre de Bruxelles, Bruxelles- Belgium ULI - University of Ljubljana, Ljiubljana- Slovenia UNISI - Universita degli Studi di Siena, Siena-Italy UOUL - Oulun Yliopisto, Oulu, Finland Participants gave written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data Availability and Code availability
The generated data is person-sensitive and access can be provided by application to the INNODIA Data Access Committee. Any additional information regarding the data reported in this paper is available from the lead contact upon request.
